Search results
Results from the WOW.Com Content Network
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
Effects of long-term benzodiazepine use may include disinhibition, impaired concentration and memory, depression, [19] [20] as well as sexual dysfunction. [6] [21] The long-term effects of benzodiazepines may differ from the adverse effects seen after acute administration of benzodiazepines. [22]
The stopping of antidepressants for example, can lead to antidepressant discontinuation syndrome. With careful physician attention, however, medication prioritization and discontinuation can decrease costs, simplify prescription regimens, decrease risks of adverse drug events and poly-pharmacy, focus therapies where they are most effective, and ...
When stopped abruptly, Wellbutrin can cause withdrawal symptoms. If you develop side effects, it’s important not to make changes to your dosage or stop using Wellbutrin without first talking to ...
Approximately 15–50% of people who suddenly stop an antidepressant develop antidepressant discontinuation syndrome. [7] [2] [3] [4] The condition is generally not serious, [2] though about half of people with symptoms describe them as severe. [4] Many restart antidepressants due to the severity of the symptoms. [4]
Dr. Pinkerton was worried that her patients—and other women across the country—would be alarmed by the news and stop the therapy that could significantly improve their quality of life: helping ...
But some research has noted rare but serious side effects of once-weekly, 2.4-milligram (mg) semaglutide injections, such as pancreatitis, acute kidney injury, gallbladder issues, and thyroid cancer.
Another example of pharmaceutical rebound is a rebound headache from painkillers when the dose is lowered, the medication wears off, or the drug is abruptly discontinued. [ 18 ] In 2022, reports of viral RNA and symptom rebound in people with COVID-19 treated with Paxlovid were published.